Jordan RE - Search Results

1

Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.

Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, Kereiakes DJ. Nakada MT, et al. Among authors: jordan re. J Thromb Thrombolysis. 2002 Aug;14(1):15-24. doi: 10.1023/a:1022058103581. J Thromb Thrombolysis. 2002. PMID: 12652146

2

Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.

Nakada MT, Montgomery MO, Nedelman MA, Guerrero JL, Cohen SA, Barnathan ES, Jordan RE. Nakada MT, et al. Among authors: jordan re. J Vasc Interv Radiol. 2004 Feb;15(2 Pt 1):169-76. doi: 10.1097/01.rvi.0000109395.74740.1f. J Vasc Interv Radiol. 2004. PMID: 14963184

3

Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.

Tam SH, Sassoli PM, Jordan RE, Nakada MT. Tam SH, et al. Among authors: jordan re. Circulation. 1998 Sep 15;98(11):1085-91. doi: 10.1161/01.cir.98.11.1085. Circulation. 1998. PMID: 9736595

4

7E3 F(ab')2, an effective antagonist of rat alphaIIbbeta3 and alphavbeta3, blocks in vivo thrombus formation and in vitro angiogenesis.

Sassoli PM, Emmell EL, Tam SH, Trikha M, Zhou Z, Jordan RE, Nakada MT. Sassoli PM, et al. Among authors: jordan re. Thromb Haemost. 2001 May;85(5):896-902. Thromb Haemost. 2001. PMID: 11372685

5

Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by site-specific pegylation.

Knight DM, Jordan RE, Kruszynski M, Tam SH, Giles-Komar J, Treacy G, Heavner GA. Knight DM, et al. Among authors: jordan re. Platelets. 2004 Nov;15(7):409-18. doi: 10.1080/09537100410001723135. Platelets. 2004. PMID: 15745312 Free article.

6

Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates.

Palmerini T, Nedelman MA, Scudder LE, Nakada MT, Jordan RE, Smyth S, Gordon RE, Fallon JT, Coller BS. Palmerini T, et al. Among authors: jordan re. J Am Coll Cardiol. 2002 Jul 17;40(2):360-6. doi: 10.1016/s0735-1097(02)01951-4. J Am Coll Cardiol. 2002. PMID: 12106945 Free article.

7

Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.

Marciniak SJ Jr, Jordan RE, Mascelli MA. Marciniak SJ Jr, et al. Among authors: jordan re. Thromb Haemost. 2001 Mar;85(3):539-43. Thromb Haemost. 2001. PMID: 11307828

8

Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs.

Brezski RJ, Luongo JL, Petrone D, Ryan MH, Zhong D, Tam SH, Schmidt AP, Kruszynski M, Whitaker BP, Knight DM, Jordan RE. Brezski RJ, et al. Among authors: jordan re. J Immunol. 2008 Sep 1;181(5):3183-92. doi: 10.4049/jimmunol.181.5.3183. J Immunol. 2008. PMID: 18713989

9

Readministration of abciximab: interim report of the ReoPro readministration registry.

Tcheng JE, Kereiakes DJ, Braden GA, Jordan RE, Mascelli MA, Langrall MA, Effron MB. Tcheng JE, et al. Among authors: jordan re. Am Heart J. 1999 Jul;138(1 Pt 2):S33-8. doi: 10.1053/hj.1999.v138.99236. Am Heart J. 1999. PMID: 10385789

10

Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates.

Deitch JS, Williams JK, Adams MR, Fly CA, Herrington DM, Jordan RE, Nakada MT, Jakubowski JA, Geary RL. Deitch JS, et al. Among authors: jordan re. Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1730-7. doi: 10.1161/01.atv.18.11.1730. Arterioscler Thromb Vasc Biol. 1998. PMID: 9812911

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

220 results

Search Page

Filters